US20030091558A1 - Storage-stable fibrinogen solutions - Google Patents

Storage-stable fibrinogen solutions Download PDF

Info

Publication number
US20030091558A1
US20030091558A1 US10/263,987 US26398702A US2003091558A1 US 20030091558 A1 US20030091558 A1 US 20030091558A1 US 26398702 A US26398702 A US 26398702A US 2003091558 A1 US2003091558 A1 US 2003091558A1
Authority
US
United States
Prior art keywords
fibrinogen
solution
maintained
stability
fibrinogen solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/263,987
Other languages
English (en)
Inventor
Christopher Woolverton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/263,987 priority Critical patent/US20030091558A1/en
Publication of US20030091558A1 publication Critical patent/US20030091558A1/en
Priority to US11/185,962 priority patent/US20060148698A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • This invention relates generally to storage-stable, concentrated fibrinogen preparations and a method of use therefor to prevent blood loss, to promote wound healing, and for many other therapeutic and non-therapeutic applications.
  • Fibrinogen is a blood plasma protein, serving a significant role in the final stage of the coagulation to preserve hemostasis and prevent blood loss in mammals. Clot formation in mammals, i.e., blood coagulation, occurs by means of a complex cascade of events in which in the final steps the monomeric form of fibrinogen reacts with thrombin and activated Factor XIII in the presence of calcium ions, to form a fibrin clot comprising a cross-linked fibrin polymer.
  • the fibrinogen monomer representing 2-4 grams/liter of blood plasma protein, consists of three pairs of disulfide-linked polypeptide chains. These are designated (A ⁇ ) 2 , (B ⁇ ) 2 , representing the two small aminoterminal peptides of the ⁇ and ⁇ chains, respectively), and ⁇ 2 . Cleavage of the fibrinopeptide A from fibrinogen by thrombin results in the compound, fibrin I, and the subsequent cleavage of fibrinopeptide B results in the final fibrin II compound.
  • fibrinogen fibrinogen, thrombin and other components, which imitate the final stages of natural coagulation, thereby resulting in a fibrin clot.
  • Called fibrin- or tissue-sealant, biological sealant, fibrin- or tissue-glue, biological adhesive, or the like (collectively referred to herein as a “fibrin sealant”), tests on such materials have shown a direct relationship between tensile strength and the final fibrinogen concentration (Japanese Patent Unexamined Published Application, Kokai No. Sho 61-293443).
  • the availability of concentrated fibrinogen is significant for the preparation of conventional fibrin sealants.
  • Tissue adhesives based on fibrinogen are known, for example from U.S. Pat. No. 6,117,425 (MacPhee et al.)
  • such formulations may also contain additional proteins, such as fibronectin and albumin, and optionally antibiotic agents, growth factors, and the like.
  • the required catalytic (thrombin-mediated) activity can either originate from the host tissue (the wound surface) to which it is applied, or it can be added in the form of a thrombin and Ca ++ ion-containing solution or powder to the tissue adhesive in the course of application.
  • Such fibrin sealants have been used for seamless and/or seam-supporting binding of human or animal tissue or organ parts, for wound sealing, hemostasis and promoting wound healing, for coating prosthetic devices, and for many other therapeutic and non-therapeutic applications.
  • the fibrinogen component of fibrin sealants is derived from pooled blood plasma, often as a waste product in the preparation of Factor VIII. Fibrinogen can be concentrated from plasma by cryoprecipitation, or by precipitation by known methods using various reagents, e.g., polyethylene glycol, ether, ethanol, ammonium sulfate or glycine. Fibrin sealants are reviewed, for example, by Brennan, Blood Reviews 5:240-244 (1991); Gibble et al., Transfusion 30:741-747 (1990); Matras, J. Oral Maxillofac. Surg. 43:605-611 (1985); Lerner et al., J. Surg. Res. 48:165-181 (1990).
  • the preparations provide effective hemostasis, good adherence of the seal to the wound and/or tissue areas, high strength of the adhesions and/or wound sealings, and complete resorbability of the adhesive in the course of the wound healing process.
  • a concentration of fibrinogen of about 15 to 60 mg/ml of the ready-to-use tissue adhesive solution is required (MacPhee, personal communication, 1995).
  • Tissue adhesives are marketed either in the form of deep-frozen solutions or as a lyophilate. This is because as a liquid solution, highly concentrated fibrinogen is known to be highly unstable (http:www.tissuesealing.com/us/products/biological/monograph. cfm), i.e., it is subject to spontaneous coagulation. Consequently, commercially available lyophilized and/or deep-frozen fibrinogen concentrates, such as Tissucol, must currently be liquefied, i.e., slowly thawed (“melted”) or reconstituted from lyophilized form before application. Both liquefaction processes, however, are associated with significant effort and a considerable time lag before the product can be used, which can place an already injured patient into a life-threatening situation.
  • the “liquefaction temperature” of the deep-frozen concentrate e.g., the point at which the preparation changes from frozen solid to liquid, requires slowly increasing the temperature of the solution—generally to at least 25° C., more often to over 37° C., with significant stirring or agitation for up to 30-60 minutes (http://www.tissuesealing.com/us/products/biological/monograph.cfm).
  • a water bath or other heating device typically at 37° C.
  • heat exchange is typically made even more difficult because of the necessary double coating packaging required, for example to maintain sterile conditions of the product, throughout the difficult and cumbersome thawing procedure.
  • heat exchange is typically made even more difficult because of the necessary double coating packaging required, for example to maintain sterile conditions of the product, throughout the difficult and cumbersome thawing procedure.
  • deep-frozen fibrin sealant preparations in pre-filled, ready-to-use, sterile disposable syringes must be double scaled in plastic film for reasons of sterility.
  • the preparation time of lyophilized fibrinogen also results in significant delays before the product can be used, which becomes a real problem in the use of currently available fibrinogen-based hemostats. Therefore, significant effort has been undertaken to improve the solubility of lyophilized fibrinogen preparations. For example, one manufacturer requires the use of a magnetic stirrer added to the vials of protein to provide significant agitation while heating. This results in dissolution times which are faster than those obtained for the same product without significant mixing, but it still requires 30-60 minutes of preparation time simply to get the fibrinogen ready to use.
  • solubility of fibrinogen preparations of the prior art is often further reduced by the implementation of virus inactivation methods. These are preferably carried out in a manner such that the lyophilized material is subjected to a heat treatment, for example according to EP 0 159 311.
  • EP-0 345 246 describes a lyophilized fibrinogen preparation which, in addition to fibrinogen, further contains at least one biologically acceptable additive (a tenside).
  • a tenside biologically acceptable additive
  • the addition of tensides results in an improved wetting of the lyophilisate with the solvent, whereby the rate of dissolution at a certain temperature is improved, but not the solubility of the fibrinogen itself. Therefore, such preparations must also be reconstituted in a surrounding temperature over 25° C., usually 37° C.
  • U.S. Pat. No. 5,962,405 provides storage-stable lyophilized or deep frozen liquid preparations of fibrinogen, which can be reconstituted and liquefied into ready-to-use fibrinogen and/or tissue adhesive solutions—preferably without the use of additional means, such as heating and/or stirring devices, to produce ready-to-use tissue adhesive solutions having a fibrinogen concentration of at least 70 mg/ml.
  • the preparations comprise fibrinogen and at least one additional substance which improves the solubility of the preparations, and/or lowers its liquefaction temperature, and reduces the viscosity of a ready-to-use tissue adhesive solution at room temperature.
  • the solubility enhancing substance selected from one or more of the following substances: benzene, pyridine, piperidine, pyrimidine, morpholine, pyrrole, imidazole, pyrazole, furan, thiazole, purine compounds or vitamins, nucleic bases, nucleosides or nucleotides, is added at a rate of 0.03-1.4 mmol per gram fibrinogen, although the relatively higher ratios of substance/fibrinogen are recommended. Additional proteins, adjuvants and additives may also be present.
  • the '405 patent claims that liquefaction of the deep-frozen, concentrated fibrinogen solution is advantageously possible in a surrounding temperature of 20°-23° C. (room temperature), as opposed to the previously required 37° C. warming conditions. Nevertheless, the method still requires storage under deep-frozen conditions (temperatures maintained at ⁇ 25° C. to below ⁇ 15° C.), and the preparations still take up to 15 minutes to liquefy.
  • U.S. Pat. No. 5,985,315 provides a stable biological pre-activated adhesive comprising fibrinogen with the addition of at least one activated coagulation factor whose activation does not depend on calcium ions.
  • the preactivated adhesive is stable in aqueous solution, i.e., the solution does not coagulate spontaneously for at least one hour at a temperature of 20°; but it can be made to coagulate about 5 minutes simply by adding calcium ions. No additional activator is required.
  • the resulting biological adhesive requires neither the addition of thrombin or prothrombin to achieve coagulation. Unfortunately, however, such a slow coagulation time would make the use of the resulting fibrin sealant impractical for use on any type of a flowing or pulsating wound.
  • the present invention comprises methods for the stable storage of ready-to-use, biocompatible mammalian fibrinogen, which despite its concentration, remains available in fluid form, and which will permit rapid and easy processing into a tissue adhesive preparation. Also provided is the sterile, storage-stable aqueous fibrinogen product resulting from the use of the present methods, wherein the fibrinogen remains ready-to-use in liquid form, it has not spontaneously clotted (i.e., formed a clot even in the absence of an activator, such as thrombin/Ca ++ ), and it retains its biological activity (i.e., the ability to rapidly form a fibrin clot upon exposure and vigorous mixing with thrombin and Ca ++ ).
  • an activator such as thrombin/Ca ++
  • the subject stored concentrated, ready-to-use, biocompatible mammalian fibrinogen is fully solubilized, the solution is aqueous, and its stability is pH and temperature dependent.
  • the product can be frozen, thawed, refrozen and re-thawed without affecting the clotting properties of the composition.
  • the exemplified mammalian fibrinogen is bovine, but the invention need not be so limited and is directed to any mammalian fibrinogen.
  • the methods of the invention provide a stable, concentrated, ready-to-use, biocompatible mammalian fibrinogen solution, wherein stability is maintained for a storage period ranging from at least one (1) day to one or more years following initial preparation.
  • the invention provides a ready-to-use fibrinogen solution, which is freshly prepared, or freshly isolated and purified from plasma, or frozen preparations of either one, and maintained under sterile conditions in a suitable container at room temperature or under refrigeration (about 4° C.), at pH levels ranging from pH 6.5 to 8.2. Stability is maintained for at least one year or more. Further provided is the ready-to-use, sterile, stable aqueous fibrinogen solution stored in accordance with the present method.
  • the invention provides for the addition of protease inhibitor(s) to the above-described ready-to-use fibrinogen solutions to enhance their storage stability. Accordingly, the invention provides a method of stably storing mammalian fibrinogen in a ready-to-use, aqueous solution, comprising freshly preparing a fibrinogen solution, or freshly isolating and purifying a fibrinogen solution from plasma under sterile conditions; adding to the fibrinogen solution an effective amount of a protease inhibitor to prevent proteolysis of the fibrinogen sample; and storing the fibrinogen solution at (i) a constant temperature ranging from about 4° C.
  • the fibrinogen solution remains liquid; (ii) at pH levels ranging from pH 6.31 to 8.1, (iii) under conditions wherein biocompatibility and biological activity of the fibrinogen is maintained. Stability is maintained for at least one year or more. Further provided is the ready-to-use, sterile, stable aqueous fibrinogen solution stored in accordance with the present method.
  • the thus-prepared and stored, ready-to-use, concentrated mammalian fibrinogen solutions may be neutralized and used without additional steps or processes in the preparation of biological tissue adhesives or sealants, including instant fibrin sealant preparations, and for other pharmacologic or cosmetic uses involving, e.g., wound healing, coagulation, fibrinogenaemia, inhibition of operative or post-operative sequelae, coating vascular prostheses, or infusion purposes, as well as for other supplemented or unsupplemented therapeutic or non-therapeutic applications in vivo or in vitro.
  • FIGS. 1A and 1B are photographs of a non-reduced (FIG. 1A) and reduced SDS PAGE (FIG. 1B) of bovine fibrinogen samples after 44 days of storage at room temperature.
  • the lanes are identical in each of the two gels.
  • the invention provides methods for the stable storage of ready-to-use fibrinogen, which despite its concentration, remains available in fluid form, and which will permit rapid and easy processing into a tissue adhesive preparation. Also provided is the storage-stable, aqueous fibrinogen product resulting from the use of the present methods.
  • the ready-to-use, aqueous fibrinogen solution of the present invention is “storage-stable” when after a period of days it remains stable in liquid form, it has not spontaneously clotted (i.e., formed a clot even in the absence of an activator, such as thrombin/Ca ++ ), and it retains its biological activity (i.e., the ability to rapidly form a fibrin clot upon exposure and vigorous mixing with thrombin and Ca ++ ).
  • the disclosed methods set forth conditions under which fibrinogen is stored in a ready-to-use, aqueous solution for a substantial period of time and remains active and stable (storage-stable).
  • activity with regard to the storage-stable fibrinogen solution refers to “biological activity” of the protein, and “biological activity” refers to the one or more activities known to be associated with fibrinogen, such as the ability to rapidly form a fibrin clot as described above, or a subset thereof, in vitro and/or in vivo. Methods to assess biological activity are known to those in the art.
  • the storage method of the present invention is applied to any fibrinogen preparation, whether isolated and purified from blood plasma, or recombinantly prepared, or whether freshly isolated, or freshly prepared from a lyophilized or deep-frozen preparation.
  • the methods of the present invention are applicable regardless of the length of time the fibrinogen preparation has been lyophilized or deep-frozen, so long as the biological activity of the freshly prepared fibrinogen solution is equivalent to a comparable sample of isolated and purified fibrinogen from plasma, and spontaneous clotting has not been induced in the solution.
  • the preferred embodiments of the invention are applicable to a crude fibrinogen product in the course of preparation, or to a final, concentrated fibrinogen preparation having greater than 90% protein purity and being greater than 95% clottable protein, or to any concentration of fibrinogen there between.
  • the bovine fibrinogen preparation had 61% protein purity and 97% clottable protein, while in other examples conducted by the inventors using human fibrinogen (data not shown), the preparation had 53% protein purity and 95% clottable protein. Nevertheless, the methods of the present invention were applicable to both.
  • the methods of storage are applied to a concentrated bovine fibrinogen preparation.
  • the storage-stable fibrinogen preparations of the present invention although highly concentrated, remain solubilized in aqueous solution making the fibrinogen particularly suitable for use in the preparation of supplemented or unsupplemented, ready-to-use biological tissue adhesives.
  • the fibrinogen is optimally stored at a concentration of 10-85 mg/ml, more preferably at a concentration of 15-75 mg/ml, even more preferably at a concentration of 30-70 mg/ml, and most preferably at a concentration of 40-65 mg/ml when is used to prepare a ready-to-use tissue adhesive preparation.
  • the concentration of fibrinogen, or fibrinogen-containing protein, in the storage-stable aqueous solution of the present invention generally ranges from 2 to 10 w/v %, preferably 4-7 w/v %.
  • the concentration of fibrinogen is determined by protein absorbance measurements at 280 nm (using 14 as the extinction of 1% fibrinogen solution).
  • the storage-stable fibrinogen of the present invention is fully solubilized in an aqueous solution, that is, in a water-based solution.
  • aqueous-based gels could also be used in the present invention, so long as such material permits the complete solubilization of the fibrinogen contained therein, and so long as the preparation is sufficiently fluid as to permit the rapid preparation of ready-to-use biological tissue adhesives or other applications following storage in accordance with the methods disclosed herein.
  • a key to the present invention is the fact that the fibrinogen solution is stably stored in ready-to-use fluid form; it is neither stored as a lyophilized preparation, nor is it in a deep frozen state.
  • fresh fibrinogen solutions are free flowing liquids that readily move along an inverted test tube, although their viscosity is typically greater than water.
  • Stored samples that are biologically active i.e., clot in the presence of thrombin and Ca ions
  • This type of clotting produces the controlled clot formed using active fibrinogen when tissue adhesives are prepared and used.
  • this type of clot is referred to herein simply as a “fibrin clot” to differentiate the process from a “spontaneous clot,” wherein the latter may occur in an unstable, concentrated fibrinogen solution, even absent thrombin or another activator.
  • Spontaneous clotting is recognized as an increase in viscosity (without exposure to an activator, e.g., thrombin and Ca ions), resulting in visibly decreased movement (flow) upon mixing.
  • an activator e.g., thrombin and Ca ions
  • aqueous fibrinogen solutions in less than 1 day, often in only a few hours or less.
  • the process is irreversible, leaving the fibrinogen useless for uses such as the preparation of a fibrin sealant.
  • the instability makes the length of time that the fibrinogen could be stored in ready-to-use form using current methods completely unpredictable, and hence, unreliable.
  • the storage-stable fibrinogen is stored in a polymer, plastic or plastic-based container, although more preferably the plastic container is polypropylene. Glass is not to be used to store fibrinogen or platelets because glass enhances spontaneous clot formation.
  • thrombin-insensitive fibrinogen Stored solutions of ready-to-use fibrinogen that do not clot with added thrombin and calcium ions and remain fluid (having viscosities similar to water) are referred to as “thrombin-insensitive.”
  • SDS-PAGE sodium dodecylsulfate polyacryamide gel electrophoresis
  • “Clot” formation is the sudden solidification of the fibrinogen solution, beyond which agitation cannot force liquid to flow from the solidified material.
  • the immobile material usually becomes macroscopically opaque white and viscoplastic.
  • Scanning electron micrographs (SEM) photographs of typical physiological or non-physiological fibrin clots are shown, for example, in Redl et al., Medizinische Welt 36:769-76 (1985).
  • the clot generally adheres to the test tube wall and cannot be dislodged by sharp tapping of the tube on a solid surface. This measurement is less subjective than gel formation, and estimated uncertainty is only ⁇ 1 second for rapidly setting samples (8-12 seconds), although it may be slightly greater for slower clotting (>100 seconds) samples.
  • the temperature of the solution during storage is not particularly restricted, so long as the fibrinogen contained therein remains stable (i.e., neither inactivated nor spontaneously clotted).
  • the preferred temperature for storage of the fibrinogen solutions of the present invention ranges from 1° to 25° C., more preferably from about 4° to about 23° C. When refrigerated, the optimal temperature is about 4° C. ⁇ 1° C. When storage is at room temperature, the optimal temperature ranges from about 20° to 25° C., more preferably from about 22° to 24° C., most preferably the temperature is about 23° C. ⁇ 1° C.
  • the pH value of the aqueous fibrinogen solution is preferably adjusted during storage to approximately pH 5 to 8, more preferably pH 6.2-7.5.
  • the optimal pH for the storage of a particular fibrinogen solution depends in part upon the temperature at which the material is to be stored, as is shown in the Tables that accompany the Examples which follow. However, in light of the information provided herein, one of ordinary skill in the art would be able to select the optimal pH for the fibrinogen solution based upon the planned storage temperature and conditions, knowing that the determining factor is whether the protein contained therein remains stable (i.e., neither inactivated nor spontaneously clotted).
  • ready-to-use bovine fibrinogen stored (without protease inhibitors) at room temperature ( ⁇ 23° C.) is optimally maintained at pH 6.5 to 9.0, preferably at approximately pH 6.5 to 8.2, to retain the ability to rapidly form a clot when the stored preparation is neutralized and exposed to thrombin/Ca ++ .
  • the optimal pH is also optimally maintained at pH 6.5 to 9.0, preferably at approximately pH 6.5 to 8.2, more preferably at pH 6.5 to 7.07 to retain the ability to rapidly form a clot when the stored preparation is neutralized and exposed to thrombin/Ca ++ (see Table 2).
  • the pH of the storage-stable fibrinogen solution is determined by the buffer in which it is stored.
  • solutions of bovine fibrinogen 50 mg protein/mL were freshly prepared in one of the following 0.1 M buffers: histidine, pH 7.24; glycine pH 9.31; or carbonate, pH 9.05 or pH 9.86.
  • the storage-stable bovine fibrinogen solution is prepared in histidine buffer, although other recognized, physiologically acceptable buffers known to the art may be used to prepare the storage-stable fibrinogen, so long as the resulting pH of the fibrinogen solution remains within the proscribed range, such that it's activity is maintained, but it remains without spontaneous clotting.
  • fibrinogen contains salts used in the isolation and purification process. As noted in the Examples, this includes sodium citrate and sodium chloride, but the presence of such salts that are a residual part of the fibrinogen purification process do not appear to affect the storage-stability of the resulting preparation. Since the purpose of the present invention is to produce a storage-stable, ready-to-use, fibrinogen solution that will retain the characteristics of a comparable, freshly prepared fibrinogen solution, the effect of the fibrinogen purification process would be the same for both. Nevertheless, the high concentrations of citrate and/or sodium may affect clotting of the stored fibrinogen preparation.
  • the present method is, therefore, effective, even if the identified salts or other chelators are present in the freshly prepared solution, and the storage stable preparation will retain the characteristics and activity of a comparable freshly-prepared solution, so long as activity is maintained during storage and spontaneous clotting is not induced by the salt or chelator.
  • sodium azide (0.025%) was added to each sample as an antimicrobial agent.
  • the antimicrobial agent may have, to some extent, induced spontaneous clotting, it does not appear to have had such an effect.
  • no antimicrobial agent is added, and sterility is preserved using known techniques.
  • antimicrobial agents are added to the extent exemplified, to avoid microbial contamination of the fibrinogen solution over long term storage. Any recognized, physiologically antimicrobial agent is acceptable for the purposes of the present invention, so long as the activity of the fibrinogen solution is maintained throughout the length of the storage and spontaneous clotting is not induced.
  • the storage-stable fibrinogen solution of the present invention may be supplemented with, and act as a carrier vehicle for: growth factor(s), drug or other compond(s) or mixtures thereof, so long as noted above, the activity of the fibrinogen solution is maintained throughout the length of the storage and spontaneous clotting is not induced.
  • growth factor growth factor
  • drug or other compond(s) or mixtures thereof growth factor(s), drug or other compond(s) or mixtures thereof
  • Such a supplemented preparation may also comprise additional components, e.g., drug(s), antibody(ies), anticoagulant(s) and other compounds that: (1) potentiate, stimulate or mediate the biological activity of the growth factor(s) or other additive(s) or component(s); (2) decrease the activities of one or more additive(s) or component(s) of the growth-factor supplemented fibrinogen or fibrin sealant or tissue adhesive prepared therefrom, wherein such activities would inhibit or destroy the growth factor(s) in the preparation; (3) allow prolonged delivery of the additive or component from a preparation, such as a fibrin sealant or tissue adhesive, made from the ready-to-use fibrinogen solution of the present invention; and (4) possess other desirable properties.
  • additional components e.g., drug(s), antibody(ies), anticoagulant(s) and other compounds that: (1) potentiate, stimulate or mediate the biological activity of the growth factor(s) or other additive(s) or component(s); (2) decrease the activities of one or more additive(s) or component
  • the contemplated additive(s) or supplement(s) are intended to also include any mutants, derivatives, truncated or other modified forms thereof, which possess similar biological activity(ies), or a subset thereof, to those of the compound or composition from which it is derived.
  • More than one additive or component may be simultaneously added to or supplied by the storage-stable fibrinogen solution of the present invention.
  • concentration of such additive(s) and/or component(s) will vary in the fibrinogen solution depending on the objective, the concentration must be sufficient to allow such compound(s) and/or composition(s) to accomplish their intended or stated purpose.
  • the amount of such supplement(s) to be added can be empirically determined by one of ordinary skill in the art by testing various concentrations and selecting that which is effective for the intended purpose and site of application. Dyes, tracers, markers and the like may also be added, for example, to examine the subsequent delivery of the material to which the fibrinogen is added.
  • protease inhibitors such as, but not limited to aprotinin (e.g., 5 ⁇ g/ml final concentration) or PPACK (e.g., 25 ⁇ M final concentration) are added in an effective amount to the stored, aqueous fibrinogen solution.
  • aprotinin e.g., 5 ⁇ g/ml final concentration
  • PPACK e.g., 25 ⁇ M final concentration
  • PI protease inhibitors
  • an effective amount of a protease inhibitor is meant that amount of PI that will prevent proteolysis of the fibrinogen sample.
  • PI does not appear to be effective for use in producing a rapid fibrinogen/thrombin product (fibrin clot) at, for example, 149 days.
  • rapid fibrinogen/thrombin clot formation was seen in storage-stable, bovine fibrinogen solution samples maintained at room temperature ( ⁇ 23° C.) at pH 6.3 to 7.07 for at least 149 days.
  • inhibitor equates to “prevention,” i.e., the PIs are initially active under the presently disclosed conditions (that is, clotting is inhibited/prevented), but then the activity of the PI declines, after which the inhibiting effect diminishes and eventually ceases.
  • the rate of decline of PI activity in the fibrinogen solution is pH and temperature dependent.
  • the fibrinogen solutions of the invention under the preferred conditions remain stable (active and not spontaneously clotted) for at least 97 days at pH 6.5 to 9.0, when stored at room temperature ( ⁇ 23° C.), and for at least 149 days at pH 6.5 to 8.1 in the presence of a protease inhibitor, when stored at ⁇ 4° C., but for only 7 days in the absence of the PI.
  • the fibrinogen solutions of the preferred embodiments of the invention comprising fibrinogen plus PI, remain stable for years at room temperature, and for months absent the PI.
  • long term storage means storage of the fibrinogen solution in ready-to-use form under the presently disclosed conditions, without substantial loss of protein activity for at least 3 days, preferably for at least 3 weeks, more preferably for at least 13 weeks, even more preferably for at least 149 days, even more preferably for at least 1 year, and most preferably for a period greater than 1 year.
  • the term is meant to further include a period of frozen storage in addition to storage in the ready-to-use form, which would add additional years to the storage of the product.
  • the present invention relates to any fibrinogen preparation, but the methods of the present invention are directed to the stable storage of ready-to-use, aqueous fibrinogen solutions from any mammalian species.
  • bovine fibrinogen is described by example, the invention is not intended to be so limiting. There appears to be no species compatibility issues associated with the use of the stored fibrinogen with other mammalian species.
  • the subject bovine fibrinogen may be used following storage in aqueous solution to prepare, e.g., a biologically compatible tissue adhesive preparation for use in or on any species of mammal.
  • fibrinogen As a blood plasma protein, fibrinogen is frequently accompanied by a risk of contamination with blood-borne pathogens, such as those possibly contaminating plasma proteins, in particular, hepatitis viruses or HIV. Therefore, one skilled in the art would readily prepare fibrinogen so as to remove potentially infectious materials. Common techniques to achieve this goal include, but are not limited to, ultrafiltration, pasturization (heating), solvent detergent treatment, radiation exposure and ultraviolet light treatment. Although virus inactivation by high heating or steam methods are impractical for biologically active protein solutions, including the present fibrinogen solutions, nanofiltration is an optional treatment for the fibrinogen solution of the present invention before placing it into the sterile storage container.
  • the aqueous solution of fibrinogen, thus heated may be further purified, if desired, and processed in a conventional manner such as by dialysis, sterilization or filtration. Also, various washing steps can be employed to remove stabilizing additives by methods known in the art.
  • the fibrinogen solutions of the present invention are ideally suited for forming a physiological fibrin structure when exposed to an activator solution, and fibrin clots are rapidly formed. This is proven by mixing the stored fibrinogen solution with an equal volume of a thrombin/CaCl 2 solution (comprising, e.g., 2.5 units/mg fibrinogen (100 units/ml) thrombin and 3-6 mM excess CaCl 2 over citrate or other chelators that may be added to solutions), as set forth in the Examples which follow.
  • a thrombin/CaCl 2 solution comprising, e.g., 2.5 units/mg fibrinogen (100 units/ml) thrombin and 3-6 mM excess CaCl 2 over citrate or other chelators that may be added to solutions
  • the resulting clot demonstrates a physiological fibrin structure, it will have the typical, spatial branched fibril structure shown when clots are formed by the action of thrombin on freshly-prepared or freshly isolated and purified bovine fibrinogen under physiological conditions, i. e., at an ionic strength of approximately 0.15 and approximately neutral pH.
  • Fibrinogen and thrombin concentrations dictate time to clot formation, clot strength, clot adhesion, and thus hemostasis.
  • the fibrinogen preparation and/or the fibrinogen-based tissue adhesive to which it is added according to the present invention has no cytotoxic effect when used as a tissue adhesive, i.e., it is “biocompatible,” meaning that it is well tolerated by cells, permits a good cell growth and offers an ideal prerequisite for good wound healing therewith. This is proven by dilution of the tissue adhesive with the equal volume of the half-isotonic or isotonic sodium chloride solution, and addition to fibroblast growth media. No damaging effect on the fibroblasts is detectable (See Redl et al., 1985).
  • the present storage-stable, ready-to-use fibrinogen solutions are prepared in a manner which meets all of the demands of a tissue adhesive, namely biocompatibility, viral safety and high adhesive strength, plus it has the advantage of simple and rapid preparation from a ready-to-use fibrinogen product.
  • tissue adhesive prepared from the storage stable fibrinogen of the present invention may be thus used in any known manner in which such biologically-prepared, supplemented or unsupplemented tissue adhesives are used, e.g., pharmacologic or cosmetic uses, including for infusion purposes, such as delivery of antibiotics, antineoplastics, anesthetics, and the like; for wound healing, coagulation, and fibrinogenaemia; for inhibition of operative or post-operative sequelae; for coating prostheses; for dressable wound sealings and for safe and sustained hemostasis, namely sealing fluid and/or air leakage, and the like in a patient.
  • pharmacologic or cosmetic uses including for infusion purposes, such as delivery of antibiotics, antineoplastics, anesthetics, and the like; for wound healing, coagulation, and fibrinogenaemia; for inhibition of operative or post-operative sequelae; for coating prostheses; for dressable wound sealings and for safe and sustained hemostasis, namely sealing fluid and/or air leakage
  • Standard research grade fibrinogen contains salts used in the isolation and purification process. This includes sodium citrate and sodium chloride. Thus, a 40 mg/ml solution of fibrinogen, contains, for example, 54 mM sodium citrate and 419 mM sodium chloride in addition to the fibrinogen. Additionally, sodium azide (0.025%) was added to each sample as an antimicrobial agent.
  • the clotting assays were completed in the following manner in general accordance with Kasper, Proc. Symposium on Recent Advances in Hemophilia Care, Los Angeles, Calif. Apr. 13-15, 1989 (in Liss, N.Y., 1990). Aliquots (100 ⁇ l) of each fibrinogen sample were added to 4 ml polypropylene test tubes. Each sample was neutralized (pH 7.0-7.3) using 0.1 M sodium hydroxide, 0.2 M histidine buffer (pH 6.0) or 0.1 M hydrochloric acid (determined in preliminary studies using larger volumes)). Thrombin was prepared as 200 units/ml with 1 M calcium chloride (3-6 mM excess of calcium over sodium citrate in fibrinogen preparations).
  • the thrombin preparation was then diluted with 0.1 M histidine buffer (pH 7.2) to a final thrombin concentration of 100 units/ml (2.5 units of thrombin per mg of fibrinogen). All samples were assayed at room temperature (23 ⁇ 2° C.).
  • Clotting was measured by timing the reaction that occurred when 100 ⁇ 1 of thrombin was added to the fibrinogen sample (100 ⁇ 1), and the mixture was vigorously mixed. Times were recorded when the solution turned to a viscous gel (a drastic slowing of the liquid being mixed) and to a solid clot (the point at which all liquid ceased movement upon mixing). The time to solid clot formation was often twice the time of gel formation.
  • bovine fibrinogen prepared as an aqueous solution in histidine buffer at pH 7.24, was stable to storage at room temperature for more than 10 weeks. However, it appeared unable to clot at 21 weeks.
  • bovine fibrinogen 39 mg protein/ml
  • PPACK 25 ⁇ M final concentration
  • aprotinin 5 ⁇ g/mL final concentration
  • Clotting results are shown for bovine fibrinogen in Table 2 at the conditions shown. TABLE 2 Clotting times for bovine fibrinogen, stored at 23° C. and 4° C., no protease inhibitors. Age in Temp. in Clotting Time (in seconds) Days ° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
US10/263,987 2001-10-03 2002-10-03 Storage-stable fibrinogen solutions Abandoned US20030091558A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/263,987 US20030091558A1 (en) 2001-10-03 2002-10-03 Storage-stable fibrinogen solutions
US11/185,962 US20060148698A1 (en) 2001-10-03 2005-07-21 Storage-stable fibrinogen solutions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32696301P 2001-10-03 2001-10-03
US10/263,987 US20030091558A1 (en) 2001-10-03 2002-10-03 Storage-stable fibrinogen solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/185,962 Continuation US20060148698A1 (en) 2001-10-03 2005-07-21 Storage-stable fibrinogen solutions

Publications (1)

Publication Number Publication Date
US20030091558A1 true US20030091558A1 (en) 2003-05-15

Family

ID=23274526

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/263,987 Abandoned US20030091558A1 (en) 2001-10-03 2002-10-03 Storage-stable fibrinogen solutions
US11/185,962 Abandoned US20060148698A1 (en) 2001-10-03 2005-07-21 Storage-stable fibrinogen solutions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/185,962 Abandoned US20060148698A1 (en) 2001-10-03 2005-07-21 Storage-stable fibrinogen solutions

Country Status (8)

Country Link
US (2) US20030091558A1 (ja)
EP (1) EP1450829A1 (ja)
JP (1) JP2005508925A (ja)
KR (1) KR20040058194A (ja)
CN (1) CN1606447A (ja)
CA (1) CA2462599A1 (ja)
IL (1) IL161261A0 (ja)
WO (1) WO2003028743A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060095016A1 (en) * 2004-10-29 2006-05-04 Kevin Pauza Injection of fibrin sealant including an anesthetic in spinal applications
US20060106364A1 (en) * 2004-10-29 2006-05-18 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US20070191781A1 (en) * 2004-10-29 2007-08-16 Mark Richards Apparatus and method for injection of fibrin sealant in spinal applications
US20070191845A1 (en) * 2006-01-31 2007-08-16 Sdgi Holdings, Inc. Expandable spinal rods and methods of use
US20110213464A1 (en) * 2004-10-29 2011-09-01 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US8986304B2 (en) 2004-10-29 2015-03-24 Bsnc Holding, Llc Injection of fibrin sealant using reconstituted components in spinal applications
CN114617903A (zh) * 2022-03-15 2022-06-14 中国人民解放军总医院第一医学中心 一种用于血浆冻干的组合物及其应用
US11426680B2 (en) * 2012-12-05 2022-08-30 Csl Behring Gmbh Hydrophobic charge induction chromatographic protein depleted solution

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005239613A (ja) * 2004-02-25 2005-09-08 Asahi Kasei Medical Co Ltd フィブリノーゲン組成液及びその製法
CN102268083B (zh) * 2010-06-07 2014-05-14 北京赛升药业股份有限公司 脱端基纤维蛋白原及其制备方法和应用
EP2616550B1 (en) * 2010-09-15 2016-02-10 Debiopharm International SA Method for separating target molecules or particles from fibrinogen-containing samples including blood components
KR101127127B1 (ko) * 2011-10-27 2012-03-21 주식회사 녹십자 고농도 피브리노겐 용액의 제조 방법 및 이를 이용한 피브린 실란트 제품의 제조방법
IL230151A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing a polymerization inhibitor
IL231792A0 (en) 2014-03-27 2014-08-31 Omrix Biopharmaceuticals Ltd Device and method for the preparation and administration of one-component fibrin glue
IL263679A (en) * 2018-12-12 2019-03-31 Omrix Biopharmaceuticals Ltd Kits, methods, and ingredients for preventing tissue adhesion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716645A (en) * 1991-09-05 1998-02-10 Baxter International Inc. Topical fibrinogen complex
US6815535B1 (en) * 1998-01-23 2004-11-09 Csl Limited Purification of fibrinogen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
DE4202667C1 (ja) * 1992-01-29 1993-05-13 Behringwerke Ag, 3550 Marburg, De
JP3591837B2 (ja) * 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用
WO2000029041A1 (de) * 1998-11-18 2000-05-25 Aventis Behring Gmbh Stabilisierte proteinzubereitungen für einen gewebekleber

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716645A (en) * 1991-09-05 1998-02-10 Baxter International Inc. Topical fibrinogen complex
US6815535B1 (en) * 1998-01-23 2004-11-09 Csl Limited Purification of fibrinogen

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233148A1 (en) * 2004-10-29 2010-09-16 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
US20060095016A1 (en) * 2004-10-29 2006-05-04 Kevin Pauza Injection of fibrin sealant including an anesthetic in spinal applications
US8986304B2 (en) 2004-10-29 2015-03-24 Bsnc Holding, Llc Injection of fibrin sealant using reconstituted components in spinal applications
US20110213464A1 (en) * 2004-10-29 2011-09-01 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US20060106364A1 (en) * 2004-10-29 2006-05-18 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US20100137816A1 (en) * 2004-10-29 2010-06-03 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8394072B2 (en) * 2004-10-29 2013-03-12 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US20070191781A1 (en) * 2004-10-29 2007-08-16 Mark Richards Apparatus and method for injection of fibrin sealant in spinal applications
US7597687B2 (en) * 2004-10-29 2009-10-06 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US20100143327A1 (en) * 2004-10-29 2010-06-10 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8403895B2 (en) * 2004-10-29 2013-03-26 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8403923B2 (en) * 2004-10-29 2013-03-26 Spinal Restoration, Inc. Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US7655026B2 (en) * 2006-01-31 2010-02-02 Warsaw Orthopedic, Inc. Expandable spinal rods and methods of use
US20070191845A1 (en) * 2006-01-31 2007-08-16 Sdgi Holdings, Inc. Expandable spinal rods and methods of use
US11426680B2 (en) * 2012-12-05 2022-08-30 Csl Behring Gmbh Hydrophobic charge induction chromatographic protein depleted solution
CN114617903A (zh) * 2022-03-15 2022-06-14 中国人民解放军总医院第一医学中心 一种用于血浆冻干的组合物及其应用

Also Published As

Publication number Publication date
WO2003028743A1 (en) 2003-04-10
CA2462599A1 (en) 2003-04-10
KR20040058194A (ko) 2004-07-03
JP2005508925A (ja) 2005-04-07
EP1450829A1 (en) 2004-09-01
US20060148698A1 (en) 2006-07-06
CN1606447A (zh) 2005-04-13
IL161261A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
US20060148698A1 (en) Storage-stable fibrinogen solutions
JP4094701B2 (ja) 貯蔵に安定なフィブリノーゲン調製物
US20050118156A1 (en) Storage-stable fibrin sealant
AU2003234743B2 (en) Storage-stable, liquid fibrinogen formulation
AU773128B2 (en) Stabilised protein preparations for a tissue adhesive
US6579537B2 (en) Method for producing fibronectin and fibrinogen compositions using a polyalkylene glycol and glycine or β-alanine
US11911448B2 (en) Stable liquid thrombin compositions
US20070014780A1 (en) Storage-stable human fibrinogen solutions
US20030091559A1 (en) Storage-stable human fibrinogen solutions
JP3867931B2 (ja) 液状フィブリノゲン製剤
Reiner Fibrin glue increasingly popular for topical surgical hemostasis
Crawford et al. Fibrin sealant reduces blood loss in total hip arthroplasty
JP2010279739A (ja) フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物
US20030224994A1 (en) Storage stable liquid sealer protein complex

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION